Meher Ben Abdelghani

Strasbourg, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer.

Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 27, 2026

Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP.

Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 14, 2026

Survival outcomes in POD1UM-303/InterAACT-2: a phase III study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer.

Survival outcomes in POD1UM-303/InterAACT-2: a phase III study of retifanlimab plus carboplatin-paclitaxel in first-line advanced squamous anal cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: March 10, 2026

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.

Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: February 15, 2026

Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus - An ancillary study of the FFCD0904 phase I and II trial.

Analysis of the relationship between body composition and the pharmacokinetics of panitumumab in the treatment of localized squamous cell carcinoma of the anus - An ancillary study of the FFCD0904 phase I and II trial.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: December 04, 2025

Erratum: Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.

Erratum: Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 28, 2025

Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment.

Circulating Tumor DNA Dynamics and Clinical Outcomes in Patients with Advanced Colorectal Cancer Treated with Cetuximab-Based Induction and Maintenance Treatment.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 22, 2025

Outcome of Metastatic Biliary Tract Cancer Harbouring IDH1 or FGFR2 Alterations: A Retrospective Observational Real-World Study from a French Cohort.

Outcome of Metastatic Biliary Tract Cancer Harbouring IDH1 or FGFR2 Alterations: A Retrospective Observational Real-World Study from a French Cohort.

Journal: Journal of clinical medicine

Published: August 11, 2025

Cell-free DNA dynamics and progression-free survival in metastatic gastroesophageal adenocarcinoma: insights from the REGIRI-PRODIGE 58 ancillary study.

Cell-free DNA dynamics and progression-free survival in metastatic gastroesophageal adenocarcinoma: insights from the REGIRI-PRODIGE 58 ancillary study.

Journal: NPJ precision oncology

Published: August 06, 2025

Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.

Impact of Lean Body Mass-Based Oxaliplatin Dose Calculation on Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer: Results of the Phase II Randomized LEANOX Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 20, 2025

Retrospective Multicentre Real-Life Study Evaluating the Efficacy of Atezolizumab Combined with Bevacizumab for the Treatment of Metastatic Hepatocellular Carcinoma: HIREAL Study.

Retrospective Multicentre Real-Life Study Evaluating the Efficacy of Atezolizumab Combined with Bevacizumab for the Treatment of Metastatic Hepatocellular Carcinoma: HIREAL Study.

Journal: Journal of hepatocellular carcinoma

Published: February 06, 2025

Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial.

Effect of 5 years of CT-scan and CEA follow-up on survival endpoints in patients with colorectal cancer: the PRODIGE-13 FFCD phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 02, 2025

Showing 1-12 of 44

Last Updated: 09/26/2026